The Law Offices of Frank R. Cruz announces an investigation of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On June 30, 2026, Unicycive disclosed that the FDA had issued a second Complete Response Letter (“CRL”) regarding the Company’s resubmitted New Drug Application for its kidney disease therapy, oxylanthanum, identifying the “same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025.”

On this news, Unicycive’s stock price fell $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026, thereby injuring investors.